文献速递儿童青少年精神心境障碍

二甲双胍用于超重或肥胖双相谱系障碍青少年:随机实用试验

Metformin for overweight and obese children and adolescents with bipolar spectrum and related mood disorders treated with second-generation antipsychotics: a randomised, pragmatic trial.
PubMed 文献 · Lancet Psychiatry · 2025-01-01

这项多中心开放标签实用随机试验纳入8-19岁超重或肥胖的双相谱系障碍患者,正在或即将使用第二代抗精神病药,比较二甲双胍联合健康饮食运动(MET+LIFE)与单用LIFE对BMI Z评分的影响。结果显示MET+LIFE在6个月和24个月时BMI Z评分改善均优于单用LIFE,但效应量较小,且胃肠道不良事件更常见。

要点

  • 两组自杀意念比例无显著差异,但MET+LIFE组胃肠道不良事件更常见。

核心结论

  • 对于使用第二代抗精神病药且超重或肥胖的双相谱系障碍青少年,二甲双胍对体重影响 modest,但多数患者获益大于风险。
  • 临床试验结果提示临床医生应考虑为此类患者处方二甲双胍。

研究设计与样本

  • 多中心、开放标签、实用平行组随机试验,在美国64个临床站点招募8-19岁超重或肥胖的双相谱系障碍青少年(正在或即将使用第二代抗精神病药)。
  • 共1565例随机分配(MET+LIFE组777例,LIFE组788例),按基线BMI百分位、是否起始第二代抗精神病药及出生性别分层,区组随机(每组6例)。
  • 共同主要结局为意向性治疗人群中6个月和24个月时年龄和性别标准化BMI Z评分的变化。

主要发现

  • MET+LIFE组胃肠道不良事件发生率是LIFE组的2-4倍。
  • 随机治疗期间两组任何自杀意念比例无显著差异(MET+LIFE组42/519,8%;LIFE组57/655,9%)。

关键数值与推荐

  • 自杀意念比例:MET+LIFE组8%(42/519),LIFE组9%(57/655),无显著差异。

临床怎么用

  • 对于使用第二代抗精神病药且超重或肥胖的双相谱系障碍青少年,可考虑处方二甲双胍以改善体重结局。
  • 处方二甲双胍时需注意胃肠道不良事件风险增加,应进行监测和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Second-generation antipsychotics are widely used to treat patients with bipolar spectrum disorders and effectively manage mood symptoms but can often cause substantial weight gain and other metabolic alterations that elevate long-term risks of cardiovascular disease and premature mortality. Metformin has been shown to be safe and efficacious for ameliorating weight gain but has not been evaluated in typical clinical settings or for more than 6 months in this population and is not widely used as standard of care. Therefore, we conducted a pragmatic clinical trial to assess the effect of metformin treatment in young people treated with second-generation antipsychotics who had a bipolar spectrum disorder along with overweight or obesity. METHODS: In this multi-site, open-label, pragmatic parallel group study, we enrolled overweight or obese youth aged 8-19 years, previously or currently diagnosed with a bipolar spectrum disorder, and treated with or starting a second-generation antipsychotic. Participants were recruited and followed at 64 clinical sites (community-based mental health centres or academic health centres) in the USA. Sites were eligible for participation if they projected an enrolment rate of at least three patients per month and a minimum total number of 90 patients. Participants were randomly assigned (1:1) to the healthy eating and physical activity (LIFE) or the metformin plus LIFE (MET plus LIFE) interventions, within eight strata defined by baseline BMI percentile (overweight [85th to <95th] vs obese [≥95th]); second-generation antipsychotic-naive (starting vs continuing a second-generation antipsychotic at baseline); and sex assigned at birth, and using block randomisation (blocks of six). The co-primary outcomes were change in age-normalised and sex-normalised BMI Z-score at 6 months and 24 months in the intention-to-treat population. People with lived experience with bipolar disorders were involved in the design, conduct, and reporting of this trial. The Patient-Centered Outcomes Research Institute identification was PCS-1406-19276 and the study was registered at ClinicalTrials.gov, NCT02515773, and is completed. FINDINGS: Between Nov 5, 2015, and Feb 10, 2022, 1633 individuals provided consent for study inclusion, 68 were excluded (26 withdrew before baseline assessments and 42 did not pass screening assessments), and 1565 were randomly assigned (777 assigned to the MET plus LIFE group and 788 assigned to the LIFE group). Data were available from 1252 participants at month 6 (565 in the MET plus LIFE group and 687 in the LIFE group), and 1299 participants at month 24 (579 in the MET plus LIFE group and 720 in the LIFE group). 829 (53%) participants were male and 736 (47%) were female. The mean age of participants was 13·9 years (SD 2·9). 1023 (65%) were White or Caucasian and 290 (19%) were Black or African American. After 6 months and 24 months, assignment to the MET plus LIFE group resulted in greater change in BMI Z-score compared with LIFE alone (month 6: standardised effect size, 0·26 [95% CI 0·15-0·37], p<0·0001; month 24, standardised effect size=0·11 [0·00-0·22]; p=0·047). Among participants taking metformin, 12 attempted suicide once and one attempted suicide twice; among participants not taking metformin, 25 attempted suicide once and three attempted suicide twice. There were no significant differences in proportions of patients with any suicidality during randomised treatment, as assessed using the Patient Health Questionnaire-9 item 9 (MET plus LIFE: 42 [8%] of 519; LIFE: 57 [9%] of 655). Gastrointestinal adverse events were 2-4 times more common in the MET plus LIFE group. INTERPRETATION: Although its effect on weight is modest, we conclude that for most patients, the benefits of metformin outweigh the risks. The findings from this trial suggest that clinicians should consider prescribing metformin for young people with bipolar spectrum disorder and related mood disorders who are overweight or obese and are treated with second-generation antipsychotics. FUNDING: Patient-Centered Outcomes Research Institute.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. DelBello MP, Welge JA, Klein CC, et al. Metformin for overweight and obese children and adolescents with bipolar spectrum and related mood disorders treated with second-generation antipsychotics: a randomised, pragmatic trial. Lancet Psychiatry. 2025. PMID: 41233082. doi:10.1016/S2215-0366(25)00273-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。